Clinical trial
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host…
NCT00186667 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186667 |
|---|---|
| Title | Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease |
| Official title | An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease, Blood and Marrow Transplant (BMT) |
| Intervention type | Procedure |
| Interventions | high dose chemotherapy and autologous hematopoietic cell transplant |
| Enrollment | 30 |
| Start date | Jan 1, 1999 |
| Primary completion | Jan 1, 2000 |
| Completion | Sep 1, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 9, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: